Show simple item record

dc.creatorJovičić, Snežana
dc.creatorIgnjatović, Svetlana
dc.creatorDajak, Marijana
dc.creatorMajkić-Singh, Nada
dc.date.accessioned2019-09-02T11:07:41Z
dc.date.available2019-09-02T11:07:41Z
dc.date.issued2006
dc.identifier.issn1434-6621
dc.identifier.urihttp://farfar.pharmacy.bg.ac.rs/handle/123456789/850
dc.description.abstractIncreased C-reactive protein (CRP) concentration within the reference interval ( lt 10.0 mg/L) is a strong predictor of cardiovascular disease (CVD) in apparently healthy adults. Cutoff points for use of CRP in estimating CVD risk are lt 1, 1-3 and > 3 mg/L for low, average and high relative risk, respectively. For measuring CRP concentrations to assess cardiovascular risk, high-sensitivity CRP ( hsCRP) assays have been developed. The aim of this study was to evaluate the analytical performance and clinical efficacy for cardiovascular risk estimation of the Olympus immunoturbidimetric latex CRP assay ( sensitive application). The comparative method used was the CardioPhase* hsCRP assay, approved by the Food and Drug Administration for use in CVD risk assessment. The imprecision of the Olympus hsCRP assay in the concentration range 0.2-10.0 mg/L was 0.38-8.16% within runs and 3.75-9.63% between runs. For method comparison studies, 194 fresh serum samples were selected to cover the interval 0.15-10.0 mg/L CRP. Comparison of the Dade Behring and Olympus methods was performed using weighted Deming regression analysis ( slope 0.99 mg/L, intercept 0.002 mg/L, S-y,S- x = 0.02 mg/L, r = 0.992) and a Bland-Altman relative difference plot (mean difference - 0.002%, SD = 0.040%). The agreement between the Dade Behring and Olympus methods for relative risk class assignments was 95.4%. Statistical analysis of the agreement between the two methods for each relative risk class showed that the differences between the methods were not statistically significant ( p lt 0.10). Although previous reports found poor performance of the Olympus CRP tests for use in cardiovascular and peripheral vascular risk estimation, our study proved good analytical performance and clinical efficacy of the Olympus hsCRP assay for this use.en
dc.publisherWalter de Gruyter Gmbh, Berlin
dc.rightsrestrictedAccess
dc.sourceClinical Chemistry and Laboratory Medicine
dc.subjectatherosclerosisen
dc.subjectcardiovascular diseaseen
dc.subjecthigh-sensitivity C-reactive proteinen
dc.subjecthsCRPen
dc.subjectimmunoturbidimetryen
dc.subjectOlympusen
dc.titleAnalytical performance and clinical efficacy for cardiovascular risk estimation of an Olympus immunoturbidimetric high-sensitivity C-reactive protein assayen
dc.typearticle
dc.rights.licenseARR
dcterms.abstractМајкић-Сингх, Нада; Дајак, Маријана; Јовичић, Снежана; Игњатовић, Светлана;
dc.citation.volume44
dc.citation.issue2
dc.citation.spage228
dc.citation.epage231
dc.citation.other44(2): 228-231
dc.citation.rankM22
dc.identifier.wos000235777200019
dc.identifier.doi10.1515/CCLM.2006.042
dc.identifier.pmid16475913
dc.identifier.scopus2-s2.0-32544456915
dc.identifier.rcubconv_1694
dc.type.versionpublishedVersion


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record